Drug profile · INN
adalimumab-aqvh
YUSIMRY
adalimumab-aqvh (YUSIMRY) is a tnf-alpha inhibitor. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Drug details — adalimumab-aqvh
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 3
- Programs
- 0
- Data quality
- 0.89
Quick answer
adalimumab-aqvh (YUSIMRY) is a tnf-alpha inhibitor. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
TNF-alpha inhibitor
Primary target: Tumor necrosis factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is adalimumab-aqvh?
adalimumab-aqvh (YUSIMRY) is a tnf-alpha inhibitor. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for adalimumab-aqvh?
YUSIMRY is a marketed brand name for adalimumab-aqvh. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of adalimumab-aqvh?
adalimumab-aqvh has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.